tetano
Editor, Senior Moderator
Euro Surveill. 2018 Mar;23(9). doi: 10.2807/1560-7917.ES.2018.23.9.18-00086.
[h=1]Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies.[/h] Rondy M[SUP]1,[/SUP][SUP]2[/SUP], Kissling E[SUP]1,[/SUP][SUP]2[/SUP], Emborg HD[SUP]3[/SUP], Gherasim A[SUP]4[/SUP], Pebody R[SUP]5[/SUP], Trebbien R[SUP]6[/SUP], Pozo F[SUP]7[/SUP], Larrauri A[SUP]4[/SUP], McMenamin J[SUP]8[/SUP], Valenciano M[SUP]2[/SUP], I-Move/I-Move Group[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
[h=4]KEYWORDS:[/h] Europe; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study
PMID: 29510782 DOI: 10.2807/1560-7917.ES.2018.23.9.18-00086
Free full text
[h=1]Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies.[/h] Rondy M[SUP]1,[/SUP][SUP]2[/SUP], Kissling E[SUP]1,[/SUP][SUP]2[/SUP], Emborg HD[SUP]3[/SUP], Gherasim A[SUP]4[/SUP], Pebody R[SUP]5[/SUP], Trebbien R[SUP]6[/SUP], Pozo F[SUP]7[/SUP], Larrauri A[SUP]4[/SUP], McMenamin J[SUP]8[/SUP], Valenciano M[SUP]2[/SUP], I-Move/I-Move Group[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
[h=4]KEYWORDS:[/h] Europe; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study
PMID: 29510782 DOI: 10.2807/1560-7917.ES.2018.23.9.18-00086
Free full text